

# Victor Montal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5131363/publications.pdf>

Version: 2024-02-01

57  
papers

1,428  
citations

448610

19  
h-index

406436

35  
g-index

64  
all docs

64  
docs citations

64  
times ranked

2615  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cortical microstructure in primary progressive aphasia: a multicenter study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 27.	3.0	10
2	Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12288.	1.2	2
3	Connectomic-genetic signatures in the cerebral small vessel disease. <i>Neurobiology of Disease</i> , 2022, 167, 105671.	2.1	1
4	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>JAMA Network Open</i> , 2022, 5, e229588.	2.8	18
5	Myelin loss in <i>C9orf72</i> hexanucleotide expansion carriers. <i>Journal of Neuroscience Research</i> , 2022, 100, 1862-1875.	1.3	4
6	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 618-628.	0.4	27
7	Multilingualism in semantic dementia: language-dependent lexical retrieval from degraded conceptual representations. <i>Aphasiology</i> , 2021, 35, 240-266.	1.4	7
8	AMYQ: An index to standardize quantitative amyloid load across PET tracers. <i>Alzheimer's and Dementia</i> , 2021, 17, 1499-1508.	0.4	11
9	Network interdigitations of Tau and amyloid $\beta$ deposits define cognitive levels in aging. <i>Human Brain Mapping</i> , 2021, 42, 2990-3004.	1.9	7
10	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	5.8	33
11	Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients. <i>Scientific Reports</i> , 2021, 11, 16805.	1.6	17
12	Association of Apolipoprotein E $\epsilon$ 4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021, 78, 937.	4.5	32
13	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. <i>Annals of Neurology</i> , 2021, 90, 407-416.	2.8	7
14	Association of cortical microstructure with amyloid $\beta$ and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. <i>Molecular Psychiatry</i> , 2021, 26, 7813-7822.	4.1	17
15	Divergent connectomic organization delineates genetic evolutionary traits in the human brain. <i>Scientific Reports</i> , 2021, 11, 19692.	1.6	4
16	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. <i>Frontiers in Neurology</i> , 2021, 12, 750543.	1.1	6
17	Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
18	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. <i>Translational Neurodegeneration</i> , 2021, 10, 50.	3.6	32

#	ARTICLE	IF	CITATIONS
19	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
20	Cortical microinfarcts along the Alzheimer's disease continuum in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
21	Transcriptome-wide characterization of the frontal cortex in FTLD.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e049569.	0.4	0
22	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	54
23	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12052.	1.2	7
24	Cortical microstructure in the amyotrophic lateral sclerosisâ€“frontotemporal dementia continuum. <i>Neurology</i> , 2020, 95, e2565-e2576.	1.5	19
25	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimerâ€™s disease-related inhibitory circuit dysfunction in adults with Down syndrome. <i>Molecular Neurodegeneration</i> , 2020, 15, 46.	4.4	21
26	AmyQ: An index to accurately measure cerebral amyloid load. <i>Alzheimer's and Dementia</i> , 2020, 16, e039735.	0.4	0
27	Oligodendroglial alterations in FTD caused by C9orf72 expansion. <i>Alzheimer's and Dementia</i> , 2020, 16, e040196.	0.4	0
28	The relationship between cortical microstructural changes and in vivo amyloidâ€“ $\beta$ and tau in aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041626.	0.4	0
29	The effect of APOE $\epsilon$ 4 in Alzheimerâ€™s disease biomarkers in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e042889.	0.4	0
30	Transcriptome characterization of the motor cortex suggests microglialâ€“related key events due to TDPâ€“43 aberrant inclusions. <i>Alzheimer's and Dementia</i> , 2020, 16, e042953.	0.4	0
31	1 Hâ€“MRS signature in Alzheimer disease in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e043346.	0.4	0
32	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet, The</i> , 2020, 395, 1988-1997.	6.3	164
33	Cortical microstructural correlates of astrogliosis in autosomal-dominant Alzheimer disease. <i>Neurology</i> , 2020, 94, e2026-e2036.	1.5	42
34	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 597-609.	1.8	44
35	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1815-1824.	1.7	104
36	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. <i>Brain</i> , 2019, 142, 1121-1133.	3.7	45

#	ARTICLE	IF	CITATIONS
37	ICA€P148: THE CORTICAL MICROSTRUCTURAL SIGNATURE OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P119.	0.4	0
38	O2â€09â€01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P558.	0.4	0
39	APPâ€derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2518-2530.	1.7	13
40	Challenges associated with biomarkerâ€based classification systems for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 346-357.	1.2	37
41	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. Neurobiology of Aging, 2018, 64, 58-67.	1.5	8
42	Cortical microstructural changes along the Alzheimer's disease continuum. Alzheimer's and Dementia, 2018, 14, 340-351.	0.4	122
43	P3â€394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P1248.	0.4	0
44	CSF sAPPÎ², YKL-40, and NfL along the ALS-FTD spectrum. Neurology, 2018, 91, e1619-e1628.	1.5	59
45	Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. Oncotarget, 2018, 9, 34691-34698.	0.8	57
46	Focal temporal pole atrophy and network degeneration in semantic variant primary progressive aphasia. Brain, 2017, 140, 457-471.	3.7	102
47	[O1â€06â€02]: BIPHASIC MODEL IN PRECLINICAL ALZHEIMER'S DISEASE: AV45 PET, CSF TAU AND CORTICAL THICKNESS. Alzheimer's and Dementia, 2017, 13, P201.	0.4	0
48	[P1â€366]: WEIGHT LOSS MIGHT BE A NONâ€COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P399.	0.4	0
49	[P3â€274]: STRUCTURAL CORRELATES OF ALZHEIMER'S DISEASE AND AGING IN DOWN SYNDROME: AN MRI STUDY. Alzheimer's and Dementia, 2017, 13, P1048.	0.4	0
50	The pitfalls of biomarkerâ€based classification schemes. Alzheimer's and Dementia, 2017, 13, 1072-1074.	0.4	5
51	Longitudinal brain structural changes in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 499-509.	0.4	65
52	[P4â€505]: CORTICAL MICROSTRUCTURAL CHANGES IN FRONTOTEMPORAL LOBAR DEGENERATION: A NEW IMAGING BIOMARKER. Alzheimer's and Dementia, 2017, 13, P1533.	0.4	0
53	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. Oncotarget, 2017, 8, 104706-104716.	0.8	51
54	P2-424: Obesity is Associated With Increased CSF Phospho-TAU Levels and Cognitive Decline in Healthy Elderly. , 2016, 12, P807-P807.		0

#	ARTICLE	IF	CITATIONS
55	<i>APOE</i> -by-sex interactions on brain structure and metabolism in healthy elderly controls. <i>Oncotarget</i> , 2015, 6, 26663-26674.	0.8	92
56	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2018-2023.	1.5	75
57	Obesity and dementia: the misleading [ldquo]obesity paradox[rdquo]. <i>Endocrine Abstracts</i> , 0, , .	0.0	0